Citations

Mayo Clinic

Clear

6668 citation(s) found for "Xu, William".

Teaching Rounds in Cardiac Electrophysiology
Stevenson, William G. , Asirvatham, Samuel J. , Asirvatham, Samuel J

Circulation: Arrhythmia and Electrophysiology | December 14, 2010 | Volume: 3 | Issue: 6 | Pages: 563-563

10.1161/circep.110.960674 | PMID 21156774 Get It

Percutaneous Cryoablation of Anterior Renal Masses: Technique, Efficacy, and Safety
Schmit, Grant D. , Atwell, Thomas D. , Leibovich, Bradley C. , Callstrom, Matthew R. , Woodrum, David A. , Charboneau, J. William, Kurup, A. Nicholas

American Journal of Roentgenology | November 22, 2010 | Volume: 195 | Issue: 6 | Pages: 1418-1422

10.2214/ajr.09.3530 | PMID 21098204 Get It

Approach to acute or subacute myelopathy
Schmalstieg, William F., Weinshenker, Brian G. , Weinshenker, Brian G

Neurology | November 4, 2010 | Volume: 75 | Issue: 18_supplement_1 | Pages: No page available

10.1212/wnl.0b013e3181fb3638 | PMID 21041766 Get It

Limited predictive ability of surrogate indices of insulin sensitivity/resistance in Asian-Indian men
Irving, Brian A. , Unni, Uma S. , Briggs, William M. , Quon, Michael J. , Muniyappa, Ranganath , Nair, K. Sreekumaran , Kurpad, Anura V.

American Journal of Physiology-Endocrinology and Metabolism | October 14, 2010 | Volume: 299 | Issue: 6 | Pages: E1106-E1112

10.1152/ajpendo.00454.2010 | PMID 20943755 Get It

Insulin resistance is highly prevalent in Asian Indians and contributes to worldwide public health problems, including diabetes and related disorders. Surrogate measurements of insulin sensitivity/resistance are used frequently to study Asian Indians, but these are not formally validated in this population. In this study, we compared the ability of simple surrogate indices to accurately predict insulin sensitivity as determined by the reference glucose clamp method. In this cross-sectional study of Asian-Indian men ( n = 70), we used a calibration model to assess the ability of simple surrogate indices for insulin sensitivity [quantitative insulin sensitivity check index (QUICKI), homeostasis model assessment (HOMA2-IR), fasting insulin-to-glucose ratio (FIGR), and fasting insulin (FI)] to predict an insulin sensitivity index derived from the reference glucose clamp method (SIClamp). Predictive accuracy was assessed by both root mean squared error (RMSE) of prediction as well as leave-one-out cross-validation-type RMSE of prediction (CVPE). QUICKI, FIGR, and FI, but not HOMA2-IR, had modest linear correlations with SIClamp(QUICKI: r = 0.36; FIGR: r = −0.36; FI: r = −0.27; P < 0.05). No significant differences were noted among CVPE or RMSE from any of the surrogate indices when compared with QUICKI. Surrogate measurements of insulin sensitivity/resistance such as QUICKI, FIGR, and FI are easily obtainable in large clinical studies, but these may only be useful as secondary outcome measurements in assessing insulin sensitivity/resistance in clinical studies of Asian Indians.
Health Status After Treatment for Coronary Artery Disease and Type 2 Diabetes Mellitus in the Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial
Brooks, Maria M. , Chung, Sheng‐Chia , Helmy, Tarek , Hillegass, William B. , Escobedo, Jorge , Melsop, Kathryn , Massaro, Elaine, McBane, Robert D. , Hyde, Pamela, Hlatky, Mark A. , Group, the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study, Group, the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study, McBane, Robert

Circulation | October 12, 2010 | Volume: 122 | Issue: 17 | Pages: 1690-1699

10.1161/circulationaha.109.912642 | PMID 20937978 Get It

Background— Health status is a key outcome for comparing treatments, particularly when mortality does not differ significantly. Methods and Results— Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) randomized 2368 patients with type 2 diabetes mellitus and stable ischemic heart disease to (1) prompt revascularization versus medical therapy and (2) insulin sensitization versus insulin provision. Randomization was stratified by the intended method of revascularization, coronary artery bypass graft surgery or percutaneous coronary intervention. The Duke Activity Status Index and RAND Energy, Health Distress, and Self-Rated Health scales were assessed at study entry and annually thereafter; linear mixed models were used to evaluate the effect of randomized treatment on these measures. Health status improved significantly from baseline to 1 year ( P <0.001) in each randomized treatment group. Compared with medical therapy, prompt revascularization was associated with significantly greater improvements in Duke Activity Status Index (1.32 points; P <0.001), Energy (1.36 points; P =0.02), and Self-rated Health (1.77 points; P =0.007) but not Health Distress (−0.47; P =0.46). These treatment effects were largely maintained over 4 years of follow-up. The effect of revascularization on the Duke Activity Status Index was significantly larger in the subgroup of patients intended for coronary artery bypass graft surgery compared with the subgroup intended for percutaneous coronary intervention. Health status did not differ significantly on any of the 4 measures between the insulin provision and insulin sensitization strategies. Conclusions— Prompt coronary revascularization was associated with small yet statistically significant improvements in health status compared with initial medical therapy among patients with diabetes mellitus and stable ischemic heart disease. Clinical Trial Registration— http://www.clinicaltrials.gov . Unique identifier: NCT00006305.
Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers
Hoff, Daniel D. Von , Stephenson, Joseph J., Rosen, Peter J., Loesch, David, Anthony, Stephen P. , Jameson, Gayle , Brown, Susan B., Cantafio, Nina, Richards, Donald , Fitch, Tom R., Wasserman, Ernesto, Green, Sylvan, Sutherland, William, Bittner, Michael , Alarcon, Arlet, Mallery, David, Penny, Robert, Borad, Mitesh J. , Fernández, Cristian

Journal of Clinical Oncology | October 4, 2010 | Volume: 28 | Issue: 33 | Pages: 4877-4883

10.1200/jco.2009.26.5983 | PMID 20921468 Get It

Purpose To compare the progression-free survival (PFS) using a treatment regimen selected by molecular profiling (MP) of a patient's tumor with the PFS for the most recent regimen on which the patient had experienced progression (ie, patient as his own control). Patients and Methods Patients with refractory metastatic cancer had tissue samples submitted for MP in two formats including formalin-fixed tissue for immunohistochemistry and fluorescent in situ hybridization assays and immediately frozen tissue for oligonucleotide microarray (MA) gene expression assays (all performed in a Clinical Laboratory Improvement Amendments [ CLIA ] –certified laboratory). The MP approach was deemed of clinical benefit for the individual patient who had a PFS ratio (PFS on MP-selected therapy/PFS on prior therapy) of ≥ 1.3. Results In 86 patients who had MP attempted, there was a molecular target detected in 84 (98%). Sixty-six of the 84 patients were treated according to MP results. Eighteen (27%) of 66 patients had a PFS ratio of ≥ 1.3 (95% CI, 17% to 38%; one-sided, one-sample P = .007). Therefore, the null hypothesis (that ≤ 15% of this patient population would have a PFS ratio of ≥ 1.3) was rejected. Conclusion It is possible to identify molecular targets in patients' tumors from nine different centers across the United States. In 27% of patients, the MP approach resulted in a longer PFS on an MP-suggested regimen than on the regimen on which the patient had just experienced progression. Issues to be considered in interpretation of this study include limited prior experience with patients as their own controls as a study end point and overall patient attrition.
Direct Medical Costs of Constipation From Childhood to Early Adulthood: A Population‐based Birth Cohort Study
Choung, Rok Seon , Shah, Nilay D. , Chitkara, Denesh K., Tilburg, Miranda A.L. van , Whitehead, William E. , Katusic, Slavica K., Locke, G. Richard, Talley, Nicholas J. , Branda, Megan E. , Choung, Rok Seon

Journal of Pediatric Gastroenterology and Nutrition | September 30, 2010 | Volume: 52 | Issue: 1 | Pages: 47-54

10.1097/mpg.0b013e3181e67058 | PMID 20890220 Get It

ABSTRACTBackground:Although direct medical costs for constipation‐related medical visits are thought to be high, to date there have been no studies examining whether longitudinal resource use is persistently elevated in children with constipation. Our aim was to estimate the incremental direct medical costs and types of health care use associated with constipation from childhood to early adulthood.Methods:A nested case‐control study was conducted to evaluate the incremental costs associated with constipation. The original sample consisted of 5718 children in a population‐based birth cohort who were born during 1976 to 1982 in Rochester, MN. The cases included individuals who presented to medical facilities with constipation. The controls were matched and randomly selected among all noncases in the sample. Direct medical costs for cases and controls were collected from the time subjects were between 5 and 18 years of age or until the subject emigrated from the community.Results:We identified 250 cases with a diagnosis of constipation in the birth cohort. Although the mean inpatient costs for cases were $9994 (95% Confidence interval [CI] 2538–37,201) compared with $2391 (95% CI 923–7452) for controls (P = 0.22) during the time period, the mean outpatient costs for cases were $13,927 (95% CI 11,325–16,525) compared with $3448 (95% CI 3771–4621) for controls (P < 0.001) during the same time period. The mean annual number of emergency department visits for cases was 0.66 (95% CI 0.62–0.70) compared with 0.34 (95% CI 0.32–0.35) for controls (P < 0.0001).Conclusions:Individuals with constipation have higher medical care use. Outpatient costs and emergency department use were significantly greater for individuals with constipation from childhood to early adulthood.
Gender, Attention-Deficit/Hyperactivity Disorder, and Reading Disability in a Population-Based Birth Cohort
Yoshimasu, Kouichi , Barbaresi, William J. , Colligan, Robert C., Killian, Jill M. , Voigt, Robert G. , Weaver, Amy L. , Katusic, Slavica K.

Pediatrics | September 28, 2010 | Volume: 126 | Issue: 4 | Pages: e788-e795

10.1542/peds.2010-1187 | PMID 20876182 Get It

OBJECTIVE: To determine the incidence of reading disability (RD) among children with and without research-identified attention-deficit/hyperactivity disorder (ADHD), separately according to gender, in a population-based birth cohort. METHOD: Subjects included all children born in 1976–1982 remaining in Rochester, Minnesota, after 5 years of age (n = 5718). Information from medical, school, and private tutorial records was abstracted. Cumulative incidence of RD, by any of 3 RD formulas, in children with and without ADHD and corresponding hazard ratios (HRs) were calculated separately according to gender. RESULTS: Cumulative incidence of RD by the age of 19 years was significantly higher in children with ADHD (51% in boys, 46.7% in girls) compared with those without ADHD (14.5% in boys, 7.7% in girls). Among children with ADHD, the risk for RD was similar in boys versus girls (HR: 1.0). However, among children without ADHD, boys were 2.0 times more likely than girls to meet RD criteria. Among girls, the HR for the risk for RD associated with ADHD (versus those without ADHD) was 8.1 (95% confidence interval: 5.7–11.5), which was significantly higher than the corresponding HR among boys (3.9 [95% confidence interval: 3.2–4.9]). CONCLUSIONS: The risk for RD is significantly greater among children with ADHD compared with those without ADHD. Among children with ADHD, the risk for RD is the same for boys and girls. However, among children without ADHD, boys are more at risk for RD than girls. Among girls, the magnitude of increased risk for RD associated with ADHD is nearly twice that among boys, because girls without ADHD are less likely to have RD than boys without ADHD.
The HIV-1 Central Polypurine Tract Functions as a Second Line of Defense against APOBEC3G/F
Hu, Chunling , Saenz, Dyana T. , Fadel, Hind J., Peretz, Mary, Poeschla, Eric M. , Walker, William H. , Hu, Chunling

Journal of Virology | September 15, 2010 | Volume: 84 | Issue: 22 | Pages: 11981-11993

10.1128/jvi.00723-10 | PMID 20844042 Get It

ABSTRACT HIV-1 and certain other retroviruses initiate plus-strand synthesis in the center of the genome as well as at the standard retroviral 3′ polypurine tract. This peculiarity of reverse transcription results in a central DNA “flap” structure that has been of controversial functional significance. We mutated both HIV-1 flap-generating elements, the central polypurine tract (cPPT) and the central termination sequence (CTS). To avoid an ambiguity of previous studies, we did so without affecting integrase coding. DNA flap formation was disrupted but single-cycle infection was unaffected in all target cells tested, regardless of cell cycle status. Spreading HIV-1 infection was also normal in most T cell lines, and flap mutant viruses replicated equivalently to the wild type in nondividing cells, including macrophages. However, spreading infection of flap mutant HIV-1 was impaired in non- vif -permissive cells (HuT78, H9, and primary human peripheral blood mononuclear cells [PBMCs]), suggesting APOBEC3G (A3G) restriction. Single-cycle infections confirmed that vif -intact flap mutant HIV-1 is restricted by producer cell A3G/F. Combining the Δ vif and cPPT-CTS mutations increased A3G restriction synergistically. Moreover, RNA interference knockdown of A3G in HuT78 cells released the block to flap mutant HIV-1 replication. Flap mutant HIV-1 also accrued markedly increased A3G-mediated G→A hypermutation compared to that of wild-type HIV-1 (a full log 10 in the 0.36 kb downstream of the mutant cPPT). We suggest that the triple-stranded DNA structure, the flap, is not the consequential outcome. The salient functional feature is central plus-strand initiation, which functions as a second line of defense against single-stranded DNA editing by A3 proteins that survive producer cell degradation by Vif.
An adult onset case of alpha‐methyl‐acyl‐CoA racemase deficiency
Smith, Emily H., Gavrilov, Dimitar K. , Oglesbee, Devin , Freeman, William D. , Vavra, Michael W, Matern, Dietrich , Tortorelli, Silvia , Gavrilov, Dimitar , Oglesbee, Devin , Freeman, William D

Journal of Inherited Metabolic Disease | September 3, 2010 | Volume: 33 | Issue: S3 | Pages: 349-353

10.1007/s10545-010-9183-6 | PMID 20821052 Get It

Abstractα‐Methyl‐acyl‐CoA‐racemase (AMACR) deficiency (OMIM 604489) is a rare peroxisomal disorder with a variable age of onset from infancy to late adulthood. We describe a 45‐year‐old male with a history of seizures who presented with relapsing encephalopathy. Laboratory studies revealed an elevated serum pristanic acid concentration, an elevated pristanic/phytanic acid ratio, as well as the previously described homozygous mutation in the AMACR gene, c.154T>C, consistent with AMACR deficiency. This homozygous mutation is associated with a variable phenotype ranging from neonatal cholestasis to late‐onset sensorimotor neuropathy. Dietary pristanic acid restriction was attempted to improve clinical status and the patient has remained in remission for more than 16 months.